WO2003025191A3 - Pseudotyped retroviral vector system - Google Patents

Pseudotyped retroviral vector system Download PDF

Info

Publication number
WO2003025191A3
WO2003025191A3 PCT/GB2002/004323 GB0204323W WO03025191A3 WO 2003025191 A3 WO2003025191 A3 WO 2003025191A3 GB 0204323 W GB0204323 W GB 0204323W WO 03025191 A3 WO03025191 A3 WO 03025191A3
Authority
WO
WIPO (PCT)
Prior art keywords
vector system
retroviral vector
pseudotyped retroviral
pseudotyped
therapeutic gene
Prior art date
Application number
PCT/GB2002/004323
Other languages
French (fr)
Other versions
WO2003025191A2 (en
Inventor
Andrew Slade
Susan Kingsman
Original Assignee
Oxford Biomedica Ltd
Andrew Slade
Susan Kingsman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0122803.0A external-priority patent/GB0122803D0/en
Application filed by Oxford Biomedica Ltd, Andrew Slade, Susan Kingsman filed Critical Oxford Biomedica Ltd
Priority to AU2002336162A priority Critical patent/AU2002336162A1/en
Priority to JP2003529964A priority patent/JP2005503162A/en
Priority to EP02770062A priority patent/EP1427836A2/en
Publication of WO2003025191A2 publication Critical patent/WO2003025191A2/en
Publication of WO2003025191A3 publication Critical patent/WO2003025191A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Abstract

The present invention relates to a retrovial vector system comprising a therapeutic gene wherein said retroviral vector system is pseudotyped with at least part of a heterologous envelope protein or a mutant, variant or homologue thereof and wherein said therapeutic gene is downstream of an internal promoter.
PCT/GB2002/004323 2001-09-21 2002-09-23 Pseudotyped retroviral vector system WO2003025191A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002336162A AU2002336162A1 (en) 2001-09-21 2002-09-23 Pseudotyped retroviral vector system
JP2003529964A JP2005503162A (en) 2001-09-21 2002-09-23 vector
EP02770062A EP1427836A2 (en) 2001-09-21 2002-09-23 Pseudotyped retroviral vector system

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0122803.0 2001-09-21
GBGB0122803.0A GB0122803D0 (en) 2001-09-21 2001-09-21 Vector
US33065901P 2001-10-26 2001-10-26
US60/330,659 2001-10-26

Publications (2)

Publication Number Publication Date
WO2003025191A2 WO2003025191A2 (en) 2003-03-27
WO2003025191A3 true WO2003025191A3 (en) 2003-09-18

Family

ID=26246569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/004323 WO2003025191A2 (en) 2001-09-21 2002-09-23 Pseudotyped retroviral vector system

Country Status (4)

Country Link
EP (1) EP1427836A2 (en)
JP (1) JP2005503162A (en)
AU (1) AU2002336162A1 (en)
WO (1) WO2003025191A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004789A1 (en) * 1994-08-17 1996-02-22 The General Hospital Corporation A method of selectively destroying neoplastic cells
WO1996030533A1 (en) * 1995-03-29 1996-10-03 Bavarian Nordic Research Institute A/S Pseudotyped retroviral particles
WO1997035994A2 (en) * 1996-03-27 1997-10-02 Bavarian Nordic Research Institute A/S Cytochrome p450 transducing retroviral vectors
US6207648B1 (en) * 1997-07-24 2001-03-27 Trustees Of Boston University Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy
WO2001066150A2 (en) * 2000-03-07 2001-09-13 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cel ls by rd114 pseudotyped retroviral vector particles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004789A1 (en) * 1994-08-17 1996-02-22 The General Hospital Corporation A method of selectively destroying neoplastic cells
WO1996030533A1 (en) * 1995-03-29 1996-10-03 Bavarian Nordic Research Institute A/S Pseudotyped retroviral particles
WO1997035994A2 (en) * 1996-03-27 1997-10-02 Bavarian Nordic Research Institute A/S Cytochrome p450 transducing retroviral vectors
US6207648B1 (en) * 1997-07-24 2001-03-27 Trustees Of Boston University Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy
WO2001066150A2 (en) * 2000-03-07 2001-09-13 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cel ls by rd114 pseudotyped retroviral vector particles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KELLY P ET AL: "Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 96, no. 4, 15 August 2000 (2000-08-15), pages 1206 - 1214, XP002190047, ISSN: 0006-4971 *
MILLER N ET AL: "TARGETED VECTORS FOR GENE THERAPY", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 9, no. 2, 1 February 1995 (1995-02-01), pages 190 - 199, XP000616414, ISSN: 0892-6638 *
SALMONS B ET AL: "CONSTRUCTION OF RETROVIRAL VECTORS FOR TARGETED DELIVERY AND EXPRESSION OF THERAPEUTIC GENES", LEUKEMIA, MACMILLAN PRESS LTD, US, vol. 9, no. SUPPL 1, 1 October 1995 (1995-10-01), pages S53 - S60, XP000575934, ISSN: 0887-6924 *

Also Published As

Publication number Publication date
EP1427836A2 (en) 2004-06-16
JP2005503162A (en) 2005-02-03
AU2002336162A1 (en) 2003-04-01
WO2003025191A2 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
WO2003012105A3 (en) Vegf isoform
EP0897985A3 (en) Consensus phytases
CA2383926A1 (en) Functional genomics using zinc finger proteins
EP1176195A4 (en) Method for controlling the activity of immunologically functional molecule
AU7117496A (en) Peptide inhibitor for viral protease derived from the transframe region of the gag-pol gene
IE900854L (en) Immunogenic regions on the E7 protein of human¹papillomavirus type 16
WO2004043382A3 (en) Enhanced variants of erythropoietin and methods of use
HUP0101089A2 (en) Novel plant plastid promoter sequence
IL145288A (en) Isolated cytokine zalpha11 ligand polypeptide and uses thereof
WO1996012809A3 (en) Nucleotide sequences of hiv-1 type (or subtype) o retrovirus antigens
WO1999061639A3 (en) Retroviral delivery system
WO2002038588A3 (en) Putrescine-n-methyltransferase promoter
WO2004035618A3 (en) Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
AU2002307510A1 (en) Cytokine protein family
AU4765396A (en) Method of preparing retroviral protease inhibitor intermediates
WO2003025191A3 (en) Pseudotyped retroviral vector system
EP0816504A3 (en) Platelet activating factor acetylhdrolase, and gene thereof
AU4333793A (en) Modified kluyveromyces yeasts, their preparation and use
EP1104310A4 (en) Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
EP1813676A3 (en) Retroviral vectors pseudotyped with influenza virus hemagglutinin for gene delivery
WO2003011014A3 (en) Novel constitutive and tissue specific plant promoters and their utilization
DK0665890T3 (en) Increased production of secreted proteins by recombinant eukaryotic cells
WO2003002728A3 (en) Prevention of retrogradation of starch
WO2002090501A3 (en) Vectors having replication, immunogenicity and/or pathogenicity under stress promoter regulation and use thereof
WO2001068846A3 (en) Transcription activator of the cited family

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002770062

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003529964

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002770062

Country of ref document: EP